Image Analysis Group (IAG), a leading figure in the realm of clinical trial imaging and AI-based biomarkers, has bolstered its U.S. operations with the launch of a new office in Cambridge, Massachusetts. This strategic move places IAG in close proximity to key biotechnology and pharmaceutical companies, enhancing its capacity to forge stronger partnerships and deliver localized support for clinical trials in the Boston area. The new office aims to facilitate IAG’s work across various therapeutic fields, including oncology, neuro-oncology, and metabolic diseases, by collaborating more closely with sponsors and contract research organizations engaged in Phase I–III clinical trials and imaging-centric development projects.
The Cambridge expansion also presents an opportunity for job creation, with IAG planning to hire in areas such as clinical imaging operations, data science, regulatory support, and business development over the coming 12 to 24 months. This new establishment will underpin IAG’s comprehensive imaging services, which encompass clinical trial design consultation, imaging protocol refinement, centralized image analysis, and regulatory-compliant data delivery. The company believes that its integration into the Boston life-sciences ecosystem will enhance collaboration with academic institutions, clinical research centers, and pharmaceutical and biotechnology firms.
Globally, IAG is active across North America, Europe, and Asia-Pacific, assisting pharmaceutical, biotechnology, and medical technology companies as well as CROs in conducting multi-center studies. The organization is committed to providing standardized imaging protocols, centralized data harmonization, and consistent imaging analysis to support international clinical trials. By establishing its presence in Cambridge, IAG aims to leverage its global operations to maintain uniformity and quality in imaging data across diverse locations.
Founded in 2007 and headquartered in London, IAG functions as an imaging Clinical Research Organization (iCRO), offering services to companies dealing with imaging-based clinical trial endpoints. Its proprietary DYNAMIKA™ platform integrates AI-driven image analysis, centralized quality control, regulatory-compliant reporting, and real-time oversight of clinical trials. This technology supports IAG’s mission across various medical fields, including oncology, inflammatory, musculoskeletal, cardiometabolic, and rare diseases.
For more information about Image Analysis Group and its services, interested parties can visit their website or reach out to their press contact, Marie Fussell, via phone or email.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.